These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16103142)

  • 1. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.
    Forsell MN; Li Y; Sundbäck M; Svehla K; Liljeström P; Mascola JR; Wyatt R; Karlsson Hedestam GB
    J Virol; 2005 Sep; 79(17):10902-14. PubMed ID: 16103142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF; Yang X; Sodroski J; Ross TM
    J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
    Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
    J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.
    Beddows S; Kirschner M; Campbell-Gardener L; Franti M; Dey AK; Iyer SP; Maddon PJ; Paluch M; Master A; Overbaugh J; VanCott T; Olson WC; Moore JP
    AIDS Res Hum Retroviruses; 2006 Jun; 22(6):569-79. PubMed ID: 16796532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Beddows S; Franti M; Dey AK; Kirschner M; Iyer SP; Fisch DC; Ketas T; Yuste E; Desrosiers RC; Klasse PJ; Maddon PJ; Olson WC; Moore JP
    Virology; 2007 Apr; 360(2):329-40. PubMed ID: 17126869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.
    Luo Z; Ren L; Zheng Y; Qi Z; Liang H; Liu Y; Hong K; Shao Y
    Vaccine; 2012 Aug; 30(36):5316-23. PubMed ID: 22749599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.
    Dosenovic P; Chakrabarti B; Soldemo M; Douagi I; Forsell MN; Li Y; Phogat A; Paulie S; Hoxie J; Wyatt RT; Karlsson Hedestam GB
    J Immunol; 2009 Sep; 183(5):3373-82. PubMed ID: 19696434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.
    Nkolola JP; Peng H; Settembre EC; Freeman M; Grandpre LE; Devoy C; Lynch DM; La Porte A; Simmons NL; Bradley R; Montefiori DC; Seaman MS; Chen B; Barouch DH
    J Virol; 2010 Apr; 84(7):3270-9. PubMed ID: 20053749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.